Abstract：
Diemailing~® Kudiezi Injection( DKI) is widely used in the treatment of cerebral infarction,coronary heart disease and angina pectoris. Long-term clinical application and related research evidence showed that DKI has a good effect in improving the clinical symptoms of cardiovascular and cerebrovascular diseases. However,this injection has not been included in any clinical practice guideline. It has been found that the use of DKI is in wrong way in clinical practice in recent years. Therefore,clinical experts from the field of cardiovascular and cerebrovascular diseases nationwide are invited to compile this expert consensus in order to guide clinicians.GRADE system is used to grade the quality of evidence according to different outcomes according to degrading factors. Then it forms the recommendation or consensus suggestion through the nominal group method. The formation of expert consensus mainly considers six factors: quality of evidence,economy,efficacy,adverse reactions,patient acceptability and others. Based on these six aspects,if the evidence is sufficient,a \" recommendation\" supported by evidence is formed,and GRADE grid voting rule is adopted. If the evidence is insufficient,a \" consensus suggestions\" will be formed,using the majority voting rule. In this consensus,the clinical indications,efficacy,safety evidences and related preliminary data of DKI were systematically and comprehensively summarized in a concise and clear format,which could provide valuable reference for the clinical use of DKI. This consensus has been approved by China association of Chinese medicine which is numbered GS/CACM 202-2019.
摘要：
碟脉灵~®苦碟子注射液(DKI)广泛应用于脑梗死的治疗,冠心病和心绞痛。长期临床应用及相关研究证据表明,DKI在改善心脑血管疾病临床症状方面具有良好的疗效。然而,这种注射尚未纳入任何临床实践指南.近年来，在临床实践中发现DKI的使用是错误的。因此,邀请全国心脑血管疾病领域的临床专家编写本专家共识，以指导临床医生。分级系统用于根据退化因素根据不同的结果对证据质量进行分级。然后通过名义组方法形成建议或共识建议。专家共识的形成主要考虑六个因素:证据质量、经济,功效,不良反应,患者的可接受性和其他。基于这六个方面,如果证据充分,形成有证据支持的“建议”，并采用分级网格投票规则。如果证据不足,将形成“共识建议”，使用多数投票规则。在这个共识中,临床适应症，功效,DKI的安全证据和相关初步数据以简洁明了的格式进行了系统全面的总结，为DKI的临床应用提供有价值的参考。该共识已获得中国中药协会批准，编号为GS/CACM202-2019。
